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infliximab [IFX]). Treatment efficacy was measured using ACR-responses (ACR20,
ACR50 or ACR70) at 6 months. ACR estimated response rates were based on ad-
justed indirect comparison (MTX as the common comparator) of published clinical
trials. Utilities were derived from EQ-5D data collected in CZP RA clinical trials.
Clinical history and resource use data came from published literature. Unit costs
(drug, administration, monitoring, and resources) were taken from Spanish routine
sources or published references (cost year 2009). Base case analysis was conducted
from the payer perspective, with a lifetime horizon, annual discounting rates of
costs and outcomes of 3.5% and inflation rate for 2009 onwards of 3%. One-way
sensitivity analyses were conducted. RESULTS: The average lifetime costs for
CZPMTX, ETAMTX, ADAMTX and IFXMTX were €140,971, €141,197, €139,148
and €136,961, respectively. The quality-adjusted life-years (QALYs) gained were
6.578, 6.462, 6.430 and 6.318, respectively. The deterministic cost-effectiveness
analysis found that CZPMTX dominated ETAMTX (lower cost, greater QALYs),
and that CZPMTX was cost-effective vs ADAMTX and IFXMTX at the €30,000/
QALY willingness-to-pay threshold (ICERs of €12,346/QALY and €15,414/QALY, re-
spectively). One-way sensitivity analyses showed that ICERs were most sensitive to
the change in annual discount rates, the model cycle (evaluation of ACR response
at 3 instead of 6 months), the analysis perspective and the estimation of utilities
(HAQ-DI mapping instead of direct evaluation from EQ-5D). CONCLUSIONS: This
analysis shows that CZPMTX is cost-effective versus the other considered TNF-
inhibitors recommended in Spain for the treatment of RA.
PMS47
THE LONG TERM COST-EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT
OF SEVERE, ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS WHO HAVE
RESPONDED INADEQUATELY TO CONVENTIONAL THERAPY
Farrell J1, Muszbek N2, Sheppard O1, Chaudhary M3, Naci H4, Kachroo S5
1MSD, Hoddesdon, Hertfordshire, UK, 2UBC, Budapest, Budapest, Hungary, 3Merck & Co. Inc,
North Wales, PA, USA, 4UBC, London, London, UK, 5MSD, 1 Merck Drive, NJ, USA
OBJECTIVES: To evaluate the cost-effectiveness of golimumab (Gol) treatment in
severe, active Ankylosing Spondylitis (AS). METHODS: A Markov model was con-
structed based upon the literature, to model the progression of a cohort of AS
patients treated with Gol and its comparators over a 20 year time frame. The
comparators considered were adalimumab (Ada) and etanercept (Eta) and all were
compared to standard care which was comprised of a combination of nonsteroidal
anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic drugs
(DMARDs), Cox-2 inhibitors and physiotherapy. Long-term efficacy was based on
regressions estimated from the Gol phase III trial (GO RAISE) and the literature.
Short-term comparative efficacy was derived from a mixed treatment comparison.
The outcome measure was quality-adjusted life-years (QALYs). Utilities were esti-
mated through use of an algorithm translating BASFI and BASDAI progression to
EQ-5D. Costs were based on the literature (long-term) and expert opinion (short-
term). Uncertainty was explored through deterministic and probabilistic sensitiv-
ity analysis (PSA). RESULTS: Compared to conventional therapy, the incremental
cost-effectiveness ratios (ICERs) of the biologic TNF- inhibitors Gol, Ada and Eta
were £30,043, £30,187 and £30,810 respectively, with the TNF- inhibitors having
similar QALYs and costs. In the sensitivity analysis, time horizon and baseline
BASFI and BASDAI scores had the biggest impact on the results. Gol was seen to
provide the greatest net monetary benefit (NMB) of all the TNF- inhibitors at all
willingness to pay (WTP) thresholds up to £30,000 per QALY. CONCLUSIONS: Gol is
a highly effective and well-tolerated therapy for the treatment of patients with
severe, active AS and represents a treatment option with similar cost-effectiveness
versus conventional care as the TNF- inhibitors currently approved by the Na-
tional Institute for Health and Clinical Excellence (NICE) in the UK.
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OBJECTIVES: To estimate the cost-utility of denosumab compared with generic
alendronate, generic risedronate, oral ibandronate, strontium ranelate and no
treatment to prevent osteoporotic fractures in Spanish postmenopausal women.
METHODS: A validated Markov cohort model was adapted to the Spanish osteopo-
rotic patient population (women aged 65 years, T-score2.5 SD and a prevalence
of morphometric vertebral fractures of 36%) to represent the possibility of transi-
tioning through different health states: well, hip fracture, vertebral fracture, wrist
fracture, other osteoporotic fractures, post-vertebral fracture, post hip fracture and
death. Efficacy data on fracture risk reduction were derived from a phase III trial for
denosumab versus placebo and a meta-analysis conducted by NICE for compara-
tors with follow-up of one to three years. The perspective of the Spanish National
Healthcare System was used and costs were referred to 2010. The model included
treatment persistence during the intended 5-year treatment period and assumed a
two year linear decline in efficacy after discontinuation. Persistence data for all
treatments were obtained from prescription data and a persistence study. Results
were presented in incremental cost-effectiveness ratios (ICERs). RESULTS: The
base-case ICERs were estimated at €17,345, €25,397, and €14,543 per QALY for de-
nosumab compared with no treatment, generic alendronate, and generic risedro-
nate. Denosumab was dominant against oral ibandronate and strontium ranelate
since resulted in lower costs and better efficacy. CONCLUSIONS: This analysis
showed that denosumab is a cost-effective treatment option compared to oral
osteoporosis treatments.
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OBJECTIVES: Rituximab (MabThera™) selectively targets B cells and represents an
effective therapeutic approach for RA in addition to existing treatments, such as
disease-modifying anti-rheumatic drugs (DMARDs) and tumour necrosis factor
(TNF) inhibitors. This study explores the cost-effectiveness of rituximab in TNF-IR
patients in the The Netherlands. METHODS: The analysis reflects efficacy of the
compared strategies based on two parameters: ACR response and HAQ score. A
network meta-analysis provided evidence on the comparative efficacy of treat-
ments based on ACR response. Evidence from the REFLEX trial and secondary
sources are used to project HAQ score changes of patients over time. Cost input for
the analysis is derived from local sources in the The Netherlands. Utility data
(EQ-5D) from a patient registry is analysed and categorised into six HAQ score
bands based on disease severity. All input is synthesised through an individual
simulation model that compares three treatment strategies after failure of a first
TNF: one sequence containing rituximab, one containing TNF (i.e. TNF-cycling) and
one containing abatecept. Uncertainty around model parameters is explored
through probabilistic sensitivity analysis. A scenario analysis uses data on loss of
productivity to estimate the indirect costs of the comparing strategies.RESULTS: In
the base-case analysis, the strategy with rituximab dominates the other strategies.
The result is the same in probabilistic sensitivity analysis where over 98% of the
samples show that the sequence with rituximab dominates both other strategies.
CONCLUSIONS:The addition of rituximabMTX in the standard of care of patients
with inadequate response to TNF treatment is estimated to be a cost-effective
strategy.
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OBJECTIVES: We developed a cost-effectiveness model of biological therapy (BT)
compared with methotrexate (MTX) alone, using a combination of information
from 150 patients at Hospital Militar in Bogota, Colombia, and from international
trials and economic aggregated data. METHODS: We designed a Markov model
with five functional states, based on Health Assessment Questionnaire (HAQ). Five
simulations were estimated through hypothetical cohorts of patients, with similar
characteristics to our observed sample, who initiated treatment in each of the five
states defined for the disease. Simulations were run for 10 and 20 years under
different scenarios. Utilities, in QALY were taken from Tufts CEA Registry. Discount
rates: 6% for costs and 1.5% for utilities. We calculated both direct and indirect
costs, converted into US dollars. RESULTS: In the ten-year base case, incremental
cost effectiveness ratios (ICER) (in US$ per additional QALY gained) for each of the
five functional states in increasing severity order, were $153,184; $139,466;
$130,281; $134,752 and $109,934,respectively. In the twenty-year base case, ICERs
were $119,025; $112,921; $108,124; $110,520 and $98,119, respectively. Total costs
were lower with MTX, despite higher indirect costs and complication costs. How-
ever, BT treatment represented more QALYs regardless of the initial state. More-
over, it is more cost-effective to start the treatment from advanced disease states.
BT would not be cost-effective in Colombia when using WHO cost-effectiveness
threshold (3 times per capita GDP of US$6200) and even less so using other thresh-
olds (US$ 50,000; €50,000 or £30,000 per QALY gained). CONCLUSIONS: BT com-
pared to MTX provides more QALYs to the patients, but at a high cost. When ICERs
were estimated for Colombia, BT would not be cost effective under usual thresh-
olds. A serious dilemma arises. We suggest establishing different thresholds for
different conditions, giving priority to chronic diseases that can lead to serious
disability.
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OBJECTIVES: There are 5 anti-TNF agents licensed for the treatment of RA in Ire-
land; adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. Re-
imbursement agencies have issued mixed approvals for their use through either a
multiple assessment process or a single technology appraisal process. Significant
uncertainties have been identified through these assessments. A multiple treat-
ment comparison of these agents, focusing on the uncertainties previously high-
lighted, in the Irish health care setting is the focus of this study. METHODS: The
Birmingham Rheumatoid Arthritis Model 2009 was used to estimate the cost effec-
tiveness of anti-TNF agents in patients with established RA who were non-re-
sponders to methotrexate. The perspective taken is that of the Irish Healthcare
Payer. Evidence synthesis of HAQ data (via a multiplier), long and short term sur-
vival data was performed in WinBUGs and used to inform the effect parameter in
the model. Irish cost data was applied. Utility mapping between HAQ, EQ-5D (re-
vised scoring) and SF-6D was used to model utility gain. Probabilistic analysis was
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